Back to top

Analyst Blog

BD Rx Inc., a subsidiary of global MedTech company Becton, Dickinson and Company (BDX - Analyst Report), has won the U.S. Food and Drug Administration (FDA) approval for Ondansetron Injection, USP 4mg/2mL (2mg/mL). It is the third drug to be launched in the BD Simplist line of prefilled generic injectables.

Deemed as the future of all injectables, the BD Simplist prefilled injectables are uniquely designed so as to reduce the number of steps in the traditional vial-and-syringe injection sequence from 20 to 12 steps. This lowers the possible risk of medication error, and at the same time, enhances patient safety and clinical outcome.

The Ondansetron Injection, USP, an injectable antiemetic, is used to stop nausea and vomiting, post surgeries. It also has applications in emetogenic cancer chemotherapy. Moreover, the drug is on the FDA shortage list owing to supply scarcity in the U.S.  This is clearly indicative of the considerable opportunity that the drug holds of capturing a significant share in the domestic market.

The FDA approval along with the huge demand in the underlying market is expected to boost the company’s sluggish U.S. business. Domestic revenues (contributing 41.3% to total revenues) inched up 1.3% year over year to $848 million in the last reported quarter.

The BD Rx business is an extension of the BDX’s pharmaceutical offerings, a leader in glass prefillable syringe manufacturing. The two other drugs that are already available in the market from the BD Simplist product line include the Metoclopramide Injection, USP and Diphenhydramine Hydrochloride Injection, USP.  Given the huge demand for acute care generic injectables, the BD Rx division plans to roll out 20 to 30 more drugs from its BD Simplist line of products within the next few years.

BDX has a Zacks Rank #3 (Hold). While we remain on the sidelines regarding Becton, Dickinson and Company, other medical stocks worth considering include Align Technology (ALGN - Analyst Report), The Cooper Companies (COO - Analyst Report) and McKesson (MCK - Analyst Report). All these stocks carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%